中信证券:维持信达生物“买入”评级 目标价79港元

智通财经
08 Apr

智通财经APP获悉,中信证券发布研报称,通过DCF模型,该行给予信达生物(01801)2025年合理股权价值为1300亿港元,对应目标价79港元,维持“买入”评级。该行称,公司2024年业绩超预期,产品收入增长强劲,利润端超预期实现non-IFRS口径下的盈利。报告提及,公司肿瘤管线全面快速推进,信迪利单保持快速增长,KRAS G12C、ROS1、EGFR、BTK四款靶向治疗产品获批上市,ADC新...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10